Splenic irradiation for splenomegaly: A systematic review
- PMID: 28063304
- PMCID: PMC7537354
- DOI: 10.1016/j.ctrv.2016.11.016
Splenic irradiation for splenomegaly: A systematic review
Abstract
Splenic irradiation (SI) is a palliative treatment option for symptomatic splenomegaly (i.e. for pain, early satiety, pancytopenia from sequestration) secondary to hematologic malignancies and disorders. The purpose of the current article is to review the literature on SI for hematologic malignancies and disorders, including: (1) patient selection and optimal technique; (2) efficacy of SI; and (3) toxicities of SI. PICOS/PRISMA methods are used to select 27 articles including 766 courses of SI for 486 patients from 1960 to 2016. The most common cancers treated included chronic lymphocytic leukemia and myeloproliferative disorders; the most common regimen was 10Gy in 1Gy fractions over two weeks, and 27% of patients received retreatment. A partial or complete response (for symptoms, lab abnormalities) was obtained in 85-90% of treated patients, and 30% were retreated within 6-12months. There was no correlation between biologically equivalent dose of radiation therapy and response duration, pain relief, spleen reduction, or cytopenia improvement (r2 all <0.4); therefore, lower doses (e.g. 5Gy in 5 fractions) may be as effective as higher doses. Grade 3-4 toxicity (typically leukopenia, infection) was noted in 22% of courses, with grade 5 toxicity in 0.7% of courses. All grade 5 toxicities were due to either thrombocytopenia with hemorrhage or leukopenia with sepsis (or a combination of both); they were sequelae of cancer and not directly caused by SI. In summary, SI is generally a safe and efficacious method for treating patients with symptomatic splenomegaly.
Keywords: Cancer; Leukemia; Lymphoma; Meta-analysis; Myelofibrosis; Palliation; Radiation oncology; Radiotherapy; Splenomegaly; Toxicity.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Figures
Similar articles
-
Low dose palliative radiotherapy for splenomegaly in hematologic disorders.Leuk Lymphoma. 2012 Mar;53(3):430-4. doi: 10.3109/10428194.2011.614708. Epub 2011 Sep 23. Leuk Lymphoma. 2012. PMID: 21848363
-
Splenic irradiation in hematologic malignancies and other hematologic disorders--single institution experience.Acta Clin Croat. 2011 Mar;50(1):29-35. Acta Clin Croat. 2011. PMID: 22034781
-
Palliative irradiation of the spleen.Am J Clin Oncol. 2003 Apr;26(2):178-83. doi: 10.1097/00000421-200304000-00016. Am J Clin Oncol. 2003. PMID: 12714892
-
Clinical indications and biological mechanisms of splenic irradiation in chronic leukaemias and myeloproliferative disorders.Radiother Oncol. 2001 Mar;58(3):235-46. doi: 10.1016/s0167-8140(00)00316-9. Radiother Oncol. 2001. PMID: 11230883 Review.
-
Low-dose splenic irradiation in symptomatic congestive splenomegaly: report of five cases with literature data.Radiat Oncol. 2014 Mar 27;9:86. doi: 10.1186/1748-717X-9-86. Radiat Oncol. 2014. PMID: 24673965 Free PMC article. Review.
Cited by
-
Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice.EJHaem. 2023 Jun 7;4(3):779-791. doi: 10.1002/jha2.734. eCollection 2023 Aug. EJHaem. 2023. PMID: 37601853 Free PMC article. Review.
-
Pretransplant Splenic Irradiation in Patients With Myeloproliferative Neoplasms.Adv Radiat Oncol. 2022 Apr 10;7(5):100964. doi: 10.1016/j.adro.2022.100964. eCollection 2022 Sep-Oct. Adv Radiat Oncol. 2022. PMID: 35647411 Free PMC article.
-
Radiotherapy for symptom palliation of splenomegaly in patients with haematological malignancies.Mol Clin Oncol. 2021 Jun;14(6):114. doi: 10.3892/mco.2021.2276. Epub 2021 Apr 7. Mol Clin Oncol. 2021. PMID: 33903820 Free PMC article.
-
Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant.Onco Targets Ther. 2021 Mar 9;14:1797-1805. doi: 10.2147/OTT.S242247. eCollection 2021. Onco Targets Ther. 2021. PMID: 33727830 Free PMC article. Review.
-
Survival after palliative radiation therapy for cancer: The METSSS model.Radiother Oncol. 2021 May;158:104-111. doi: 10.1016/j.radonc.2021.02.011. Epub 2021 Feb 19. Radiother Oncol. 2021. PMID: 33610623 Free PMC article.
References
-
- Sager O, Beyzadeoglu M, Dincoglan F, et al. Adaptive splenic radiotherapy for symptomatic splenomegaly management in myeloproliferative disorders. Tumori 2015;101(1):84–90. - PubMed
-
- Bickenbach KA, Gonen M, Labow DM, et al. Indications for and efficacy of splenectomy for haematological disorders. Br J Surg 2013;100(6):794–800. - PubMed
-
- Senn N A case of spleno-medullary leukemia successfully treated by the use of the roentgen ray. Med Rec 1903;63:281.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous